Severe thrombocytopenia related to long-term trastuzumab exposure

Tumori. 2013 Jan-Feb;99(1):e1-2. doi: 10.1177/030089161309900122.

Abstract

Drug-induced immune thrombocytopenia may occur secondary to several chemotherapeutic agents or new targeted monoclonal antibodies, but thrombocytopenia induced by trastuzumab is a very rare occurrence. We report a case of severe thrombocytopenia related to the administration of trastuzumab six months after the first exposure.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / immunology
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / immunology
  • Breast Neoplasms / drug therapy
  • Female
  • Humans
  • Middle Aged
  • Molecular Targeted Therapy / methods
  • Receptor, ErbB-2 / immunology*
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / immunology*
  • Time Factors
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab